Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Archemix has announced that ARC1779, a first-in-class anti-platelet agent, has received orphan drug designation from the FDA.
Subscribe to our email newsletter
ARC1779, a novel aptamer therapeutic agent, is indicated for the treatment of a rare, life-threatening blood disorder known as thrombotic thrombocytopenic purpura, or TTP.
ARC1779 is currently in Phase II clinical development with a clinical trial designed to assess the safety, pharmacokinetics and pharmacodynamic effects of ARC1779 in approximately 28 patients with vWF-mediated platelet function disorders, including acute TTP.
Errol DeSouza, president and CEO of Archemix, said: “To date we have been encouraged by ARC1779’s early-stage clinical results, and we continue to believe it has the potential to offer a new and effective treatment in a disease for which there is currently no drug therapy available.”